Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Gains from Sales and Divestitures: 2020-2025

Historic Gains from Sales and Divestitures for Tango Therapeutics (TNGX) over the last 3 years, with Sep 2025 value amounting to $454,414.

  • Tango Therapeutics' Gains from Sales and Divestitures rose 79.53% to $454,414 in Q3 2025 from the same period last year, while for Sep 2025 it was $454,414, marking a year-over-year increase of 79.53%. This contributed to the annual value of $260,865 for FY2024, which is 595.64% up from last year.
  • Tango Therapeutics' Gains from Sales and Divestitures amounted to $454,414 in Q3 2025, which was up 4.83% from $433,483 recorded in Q2 2025.
  • Tango Therapeutics' 5-year Gains from Sales and Divestitures high stood at $454,414 for Q3 2025, and its period low was $37,500 during Q2 2023.
  • In the last 3 years, Tango Therapeutics' Gains from Sales and Divestitures had a median value of $242,793 in 2024 and averaged $232,226.
  • As far as peak fluctuations go, Tango Therapeutics' Gains from Sales and Divestitures plummeted by 67.45% in 2021, and later skyrocketed by 595.64% in 2024.
  • Over the past 4 years, Tango Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $256,598 in 2021, then reached $37,500 in 2023, then spiked by 595.64% to $260,865 in 2024, then soared by 79.53% to $454,414 in 2025.
  • Its last three reported values are $454,414 in Q3 2025, $433,483 for Q2 2025, and $377,485 during Q1 2025.